Get the Stockscreener App
1.95
1.52%
-0.03
After Hours:
2.04
0.09
+4.62%
Imunon Inc stock is traded at $1.95, with a volume of 25,644.
It is down -1.52% in the last 24 hours and down -5.34% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
See More
Previous Close:
$1.98
Open:
$2.03
24h Volume:
25,644
Relative Volume:
0.50
Market Cap:
$8.19M
Revenue:
$125.00K
Net Income/Loss:
$-14.64M
P/E Ratio:
-0.3774
EPS:
-5.1674
Net Cash Flow:
$-15.06M
1W Performance:
+9.55%
1M Performance:
-5.34%
6M Performance:
-50.26%
1Y Performance:
-79.52%
1-Day Range:
$1.95
$2.04
1-Week Range:
$1.75
$2.18
52-Week Range:
$1.70
$10.40
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.95 | 8.32M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imunon Inc Stock (IMNN) Latest News
Insider Sell: Susan Eylward Sells Shares of Imunon Inc (IMNN) - GuruFocus
Imunon general counsel Susan Eylward sells $1,729 in company stock - Investing.com
Form 4 Imunon Inc For: 7 July By Investing.com - Investing.com Canada
Imunon (IMNN) Executive Chairman receives 4,410-share stock grant as salary - Stock Titan
Imunon (IMNN) CFO Joshua Blacher files initial insider Form 3 ownership report - Stock Titan
Imunon (IMNN) General Counsel reports stock grant and 920-share sale - Stock Titan
Imunon (IMNN) CMO granted stock in lieu of part of salary - Stock Titan
Imunon (IMNN) CEO Stacy Lindborg receives stock grant instead of cash salary - Stock Titan
Imunon 1Q Loss/Shr 84c >IMNN - Moomoo
IMNNImunon Inc Latest SEC Filings - Finviz
IMUNON announces executive transition: Josh Blacher appointed interim CFO as Jeffrey Church retires - MSN
Imunon (IMNN) Reorganizes Financial Leadership Ahead of CFO Tran - GuruFocus
Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed - TipRanks
ImunonJeffrey Church To Retire As Interim CFO Effective July 1, 2026SEC Filing - TradingView
Imunon Names Josh Blacher Interim Chief Financial Officer - TipRanks
Imunon CFO Jeffrey Church to Retire; Josh Blacher Named Interim CFO - TradingView
Imunon (NASDAQ: IMNN) appoints Josh Blacher as interim CFO - Stock Titan
Imunon, Inc. Appoints Josh Blacher as Principal Financial Officer and Principal Accounting Officer, Effective July 1, 2026 - marketscreener.com
Insider Sell: Susan Eylward Sells 11,800 Shares of Imunon Inc (I - GuruFocus
Form 4 Imunon Inc For: 29 June By Investing.com - Investing.com South Africa
Imunon (IMNN) Chief Medical Officer granted 21,896 shares in lieu of 2025 cash bonus - Stock Titan
Imunon (IMNN) counsel gets stock bonus, then sells 11,800 shares - Stock Titan
Imunon (IMNN) chair takes half of 2025 cash bonus in stock grant - Stock Titan
Imunon (IMNN) CEO awarded 67,150 shares instead of cash bonus - Stock Titan
Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN) - MSN
Enterprise value to EBITDA forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Price to earnings forward of Imunon, Inc. – DUS:CBO0 - TradingView
Price to sales forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Enterprise value to revenue forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Price to book forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Imunon, Inc. Actuals & Estimates (FWB:CBO0) - TradingView
Enterprise value to EBITDA forward of Imunon, Inc. – DUS:CBO0 - TradingView
Imunon, Inc. Actuals & Estimates (MUN:CBO0) - TradingView
Imunon, Inc. Actuals & Estimates (DUS:CBO0) - TradingView
Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor ForumSlideshow (NASDAQ:IMNN) 2026-06-26 - Seeking Alpha
Imunon, Inc. Actuals & Estimates (NASDAQ:IMNN) - TradingView
A41CNR Forecast — Price Target — Prediction for 2027 - TradingView
IMNN Forecast — Price Target — Prediction for 2027 - TradingView
IMNN: IMNN-001 shows unprecedented survival benefit in ovarian cancer, advancing in Phase 3 trials - TradingView
Form 4 Imunon Inc For: 23 June By Investing.com - Investing.com South Africa
Form 4 Imunon Inc For: 23 June - Investing.com UK
Imunon (IMNN) executive chair granted 4,629 shares in lieu of cash pay - Stock Titan
Imunon (IMNN) CEO Stacy Lindborg gets 1,803-share stock grant in lieu of salary - Stock Titan
Imunon’s ovarian cancer trial continues after committee review By Investing.com - Investing.com India
Imunon (IMNN) Phase 3 Trial Receives Green Light from Data Monit - GuruFocus
Imunon (IMNN) Phase 3 Trial Receives Green Light from Data Monitoring Committee - GuruFocus
Imunon’s ovarian cancer trial continues after committee review - Investing.com
IMUNON’s Phase 3 OVATION 3 Trial in Advanced Ovarian Cancer Recommended to Continue by Independent Data Monitoring Committee - Quiver Quantitative
IMUNON ovarian cancer trial stays on track after safety review - Stock Titan
IMUNON to Present at the Life Sciences Investor Forum on June 25th - GlobeNewswire
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):